文献速递角膜与眼表疾病眼外伤

角膜缘干细胞移植术治疗严重角膜化学伤后角膜缘干细胞缺乏症的系统评价

Keratolimbal allograft for limbal stem cell deficiency after severe corneal chemical injury: a systematic review.
PubMed 文献 · Br J Ophthalmol · 2017-11-15

该系统评价检索多个数据库,纳入6篇报告,分析角膜缘干细胞移植术(KLAL)治疗严重角膜化学伤后角膜缘干细胞缺乏症(LSCD)的结局,无随机对照研究,共分析33例患者36只眼,其中29只眼末次随访时69%(20/29)最佳矫正视力≥20/200,89%(32/36)术眼同期或后续行穿透性角膜移植术,证据质量低。

要点

  • 严重角膜化学伤后KLAL可查结局的研究数量有限,结局报告存在变异。
  • 29只眼末次随访时69%(20/29)最佳矫正视力≥20/200。
  • 89%(32/36)术眼同期或后续行穿透性角膜移植术。

核心结论

  • 严重角膜化学伤后KLAL可辨别结局的研究数量有限,结局报告存在变异。
  • 支持KLAL用于严重化学性角膜烧伤所致LSCD的证据质量低。
  • 需要标准化和更长随访以更好定义角膜化学伤后失明手术干预的循证最佳实践。

研究设计与样本

  • 系统评价,检索MEDLINE、EMBASE、Science Citation Index、CINAHL、LILACS和Cochrane Library。
  • 共识别6篇报告,无随机对照研究,分析33例患者36只眼的KLAL结局。
  • 其中1篇研究7只眼未明确化学伤特异性KLAL随访;其余26例患者29只眼中位术后随访42个月(范围6.2-114个月)。
  • PROSPERO注册号CRD42017054733。

主要发现

  • 29只眼中69%(20/29)末次随访时最佳矫正视力≥20/200。
  • 全部36只眼中89%(32/36)同期或后续行穿透性角膜移植术。

关键数值与推荐

  • 主要结局指标为末次随访时最佳矫正视力≥20/200的患眼比例。
  • 29只眼中69%(20/29)达到最佳矫正视力≥20/200。
  • 全部36只眼中89%(32/36)同期或后续行穿透性角膜移植术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 可辨别KLAL在严重角膜化学伤眼中结局的研究数量有限。
  • 结局报告存在变异。
  • 支持KLAL用于严重化学性角膜烧伤所致LSCD的证据质量低。
  • 需要标准化和更长随访以更好定义循证最佳实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the published literature on outcomes of keratolimbal allograft (KLAL) for the surgical treatment of limbal stem cell deficiency (LSCD) and corneal blindness after severe corneal chemical injury. METHODS: Literature searches were conducted in the following electronic databases: MEDLINE, EMBASE, Science Citation Index, CINAHL, LILACS and the Cochrane Library. Standard systematic review methodology was applied. The main outcome measure was the proportion of eyes with best-corrected visual acuity (BCVA) ≥20/200 at last follow-up. Other measures of allograft success were also collected. RESULTS: We identified six reports in which KLAL outcomes in the eyes after chemical injury could be distinguished. There were no randomised controlled studies. The outcomes of KLAL in 36 eyes of 33 patients were analysed. One study with seven eyes did not specify KLAL follow-up specific to chemical injury. Median postoperative follow-up for the other 29 eyes in 26 patients was 42 months (range 6.2-114 months). In the same 29 eyes, 69% (20/29) had BCVA ≥20/200 at the last follow-up examination. Eighty-nine per cent of all eyes (32/36) underwent penetrating keratoplasty simultaneous or subsequent to KLAL. CONCLUSIONS: The number of studies where outcomes of KLAL in eyes with severe corneal chemical injury could be discerned was limited, and variability was observed in outcome reporting. The quality of evidence to support the use of KLAL in LSCD in severe chemical corneal burns was low. Standardisation and longer follow-up are needed to better define evidence-based best practice when contemplating surgical intervention for blindness after corneal chemical injury. PROSPERO REGISTRATION NUMBER: CRD42017054733.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shanbhag SS, Saeed HN, Paschalis EI, et al. Keratolimbal allograft for limbal stem cell deficiency after severe corneal chemical injury: a systematic review. Br J Ophthalmol. 2017. PMID: 29141906. doi:10.1136/bjophthalmol-2017-311249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。